EU invests 10 million euro in unlocking technologies for key research in structural biology
To enable researchers from European institutes to extend innovative structural biology research, the EU has invested 10 million euro to iNEXT-Discovery, through its Horizon 2020 program.
The iNEXT-Discovery consortium incorporates the Astbury Centre at the University of Leeds, and a total of 23 partners from 14 European countries. It aims to facilitate the generation of knowledge for the development of new drugs, advanced vaccines, novel biomaterials, engineered enzymes for food production, efficient biofuels, and other benefits. iNEXT-Discovery will do that by enabling leading European facilities to offer advanced technological instrumentation and expertise to all European scientists, allowing them to perform high-end structural biology research with state-of-the-art equipment that is often unavailable in their home countries.
Advancing technologies beyond the state of the art
Joining forces within the iNEXT-Discovery consortium also enables the partners to collaborate in joint research activities that will allow new and better ways to perform structural biology experiments. iNEXT-Discovery will build on the expertise of the partners to: further consolidate the strong role of structural biology in drug development by developing fragment-based lead discovery; develop tools to increase the throughput for electron microscopy and serial X-ray crystallography; integrate structural biology technologies; push nuclear magnetic resonance (NMR) spectroscopy and other technologies to better describe time scales, molecular states and dynamics; and integrate structural biology approaches for imaging cells.
Enabling research without borders
iNEXT-Discovery includes partners from institutions outside of the facility providers that also collaborate on planned joint research projects. Prof. Dr. Anastassis Perrakis, the iNEXT-Discovery coordinator from the Division of Biochemistry at the NKI and Oncode Institute explains: “Together with regional experts, specifically from the Baltic and Balkan countries, and with five ESFRI communities in the fields of health, biotechnology, and food, we are offering cutting-edge technologies and novel experimental possibilities to all European scientists, enabling experiments that would be impossible without our facilities”. Integration will be further enabled through the extensive and inclusive training program that the iNEXT-Discovery has developed, and that will be deployed in the coming four years.
How to access iNEXT-Discovery facilities
Access to all facilities will be available through an open peer review system that is based on scientific excellence and the potential of each project for enabling translational research. While iNEXT-Discovery expects Open Access publication from all users, it also enables researchers from industry to access its facilities as a fee-for-service, through a dedicated access portal. Starting from the 1st of February 2020, iNEXT-Discovery will be open for applications.
iNEXT-Discovery and the University of Leeds
Dr Rebecca Thompson, Senior Cryo-Electron Microscopy Support Scientist and Facility Manager for the Electron Microscopy Facility within the Astbury Biostructure Laboratory, said: “In this scheme we will welcome researchers from across the EU to our electon microscopy facility not only to collect data, but also to help develop projects and take them from test-tube to structure. By making the technology and expertise we have here at the University of Leeds available to the wider community, we hope to facilitate whole range of exciting science.
“We are delighted to be a part of iNEXT discovery and look forward to welcoming researchers from across the EU to our facility.”
Structural biology is of paramount importance for basic research in biochemistry, biomedicine and biotechnology, and key for fundamental innovations in health, environment and green economy. Structural biology unravels the 3D-structures of biological macromolecules, helping scientists to understand their roles within the intricate machinery of life, design new macromolecules with better properties for industry or for health, or develop small molecules that interfere with function and can be developed as the drugs of tomorrow. In the past and the present, Europe remains in a leading position in this research area.
For further information please contact Rebecca Thompson on firstname.lastname@example.org